Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | MTOR | P42345 | 1/20 | 0.73 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.73 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.73 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.73 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | GLA | P06280 | 1/20 | 0.62 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.59 |
| ▸ | ST6GAL1 | P15907 | 4/20 | 0.56 |
| ▸ | P2RY4 | P51582 | 1/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17304691 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL15338532 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL158513 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL18231346 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL13524621 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL2811458 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL14178411 | 1.00 | LMNA (0.73) | LMNATHRBMTORMDM2NCOA1 | |
| Trifluoroacetic Acid SCHEMBL4666697 | 0.92 | LMNA (0.62) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL5964221 | 0.91 | LMNA (0.70) | LMNATHRBMTORMDM2NCOA1 | |
| SCHEMBL888543 | 0.90 | LMNA (0.66) | LMNATHRBMTORMDM2NCOA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 563 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637673-B2 | Compositions and methods for splicing modulation OF UNC13A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-05-26 | — | — | US | claimed |
| US-12612630-B2 | Compositions and methods for splicing modulation of UNC13A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2026-04-28 | — | — | US | claimed |
| US-20250304964-A1 | COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-10-02 | — | — | US | claimed |
| US-20250283083-A1 | COMPOSITIONS AND METHODS FOR SPLICING MODULATION OF UNC13A | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-09-11 | — | — | US | claimed |
| EP-4605009-A2 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GanNA Bio, Inc. (US) | 2025-08-27 | — | — | EP | claimed |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | GANNA BIO, INC. | 2025-07-31 | — | — | US | claimed |
| US-20240376473-A1 | ANTISENSE COMPOUND FOR MODULATING WFDC2 EXPRESSION | QMINE CO., LTD. (KR) | 2024-11-14 | — | — | US | claimed |
| WO-2024191271-A1 | DOUBLE-STRANDED RNA REGULATING EXPRESSION OF WFDC2 AND USE THEREOF | 주식회사 큐마인 | 2024-09-19 | — | — | WO | claimed |
| WO-2024186156-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIVER DISEASES COMPRISING ANTISENSE COMPOUND THAT REGULATES EXPRESSION OF WFDC2 | 주식회사 큐마인 | 2024-09-12 | — | — | WO | claimed |
| EP-4403634-A1 | ANTISENSE COMPOUND THAT REGULATES EXPRESSION OF WFDC2 | Qmine Co., Ltd. (KR) | 2024-07-24 | — | — | EP | claimed |
| WO-2014144761-A2 | INCREASING SPECIFICITY FOR RNA-GUIDED GENOME EDITING | THE GENERAL HOSPITAL CORPORATION (US) | 2014-09-18 | — | — | WO | claimed |
| EP-2600901-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | Moderna Therapeutics, Inc. (US) | 2013-06-12 | — | — | EP | claimed |
| EP-2221376-B1 | Antisense modulation of superoxide dismutase 1, soluble expression | ISIS PHARMACEUTICALS INC (US) | 2012-11-21 | — | — | EP | claimed |
| US-20120065252-A1 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | ARES CAPITAL CORPORATION, AS AGENT | 2012-03-15 | — | — | US | claimed |
| WO-2012019168-A2 | ENGINEERED NUCLEIC ACIDS AND METHODS OF USE THEREOF | MODERNA THERAPEUTICS, INC. (US) | 2012-02-09 | — | — | WO | claimed |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-31 | — | — | US | claimed |
| US-7235653-B2 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. (US) | 2007-06-26 | — | — | US | claimed |
| US-20040235164-A1 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | ISIS PHARMACEUTICALS, INC. | 2004-11-25 | — | — | US | claimed |
| US-6545162-B1 | Solid phase biosynthesis of viricide antibiotic | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2003-04-08 | — | — | US | claimed |
| US-6174868-B1 | ANTISENSE OLIGONUCLEOTIDES WHICH ARE COMPLEMENTARY TO AND HYBRIDIZABLE WITH HCV RNA; INHIBITS THE FUNCTION OF THE GENOME AND MESSENGER RNA; PROPHYLAXIS AND THERAPY; MEDICAL DIAGNOSIS/DETECTION OF THE VIRUS AND ASSOCIATED DISEASE | ISIS PHARMACEUTICALS, INC. | 2001-01-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637673-B2 | Compositions and methods for splicing modulation OF UNC13A | NSUN2, UPF1, METTL16 | LMNA 335/4885THRB 2612/4885MTOR 4727/4885 |
| US-20040235164-A1 | Oligonucleotide compositions and methods for the modulation of the expression of B7 protein | CD2BP2, MICA, CD74 | LMNA 3875/4885THRB 3651/4885MTOR 4783/4885 |
| US-20080027019-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS FOR THE MODULATION OF THE EXPRESSION OF B7 PROTEIN | CD2BP2, MICA, CD74 | LMNA 3875/4885THRB 3651/4885MTOR 4783/4885 |
| US-20250242035-A1 | GLYCAN CONJUGATE COMPOSITIONS AND METHODS | SIGLEC7, SIGLEC9, ENGASE | LMNA 2959/4885THRB 1350/4885MTOR 2671/4885 |
| US-12612630-B2 | Compositions and methods for splicing modulation of UNC13A | UPF1, NSUN2, NSUN3 | LMNA 291/4885THRB 2305/4885MTOR 4509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.